» Articles » PMID: 35777848

Characterization of -Specific Th22 Cells and the Effect of Tuberculosis Disease and HIV Coinfection

Overview
Journal J Immunol
Date 2022 Jul 1
PMID 35777848
Authors
Affiliations
Soon will be listed here.
Abstract

The development of a highly effective tuberculosis (TB) vaccine is likely dependent on our understanding of what constitutes a protective immune response to TB. Accumulating evidence suggests that CD4 T cells producing IL-22, a distinct subset termed "Th22" cells, may contribute to protective immunity to TB. Thus, we characterized -specific Th22 (and Th1 and Th17) cells in 72 people with latent TB infection or TB disease, with and without HIV-1 infection. We investigated the functional properties (IFN-γ, IL-22, and IL-17 production), memory differentiation (CD45RA, CD27, and CCR7), and activation profile (HLA-DR) of -specific CD4 T cells. In HIV-uninfected individuals with latent TB infection, we detected abundant circulating IFN-γ-producing CD4 T cells (median, 0.93%) and IL-22-producing CD4 T cells (median, 0.46%) in response to The frequency of IL-17-producing CD4 T cells was much lower, at a median of 0.06%. Consistent with previous studies, IL-22 was produced by a distinct subset of CD4 T cells and not coexpressed with IL-17. -specific IL-22 responses were markedly reduced (median, 0.08%) in individuals with TB disease and HIV coinfection compared with IFN-γ responses. -specific Th22 cells exhibited a distinct memory and activation phenotype compared with Th1 and Th17 cells. Furthermore, -specific IL-22 was produced by conventional CD4 T cells that required TCR engagement. In conclusion, we confirm that Th22 cells are a component of the human immune response to TB. Depletion of -specific Th22 cells during HIV coinfection may contribute to increased risk of TB disease.

Citing Articles

T Cell Responses during Human Immunodeficiency Virus/ Coinfection.

Bohorquez J, Jagannath C, Xu H, Wang X, Yi G Vaccines (Basel). 2024; 12(8).

PMID: 39204027 PMC: 11358969. DOI: 10.3390/vaccines12080901.


Design and Characterization of a Multistage Peptide-Based Vaccine Platform to Target Infection.

Bellini C, Vergara E, Bencs F, Fodor K, Bosze S, Krivic D Bioconjug Chem. 2023; 34(10):1738-1753.

PMID: 37606258 PMC: 10587871. DOI: 10.1021/acs.bioconjchem.3c00273.

References
1.
Zhang M, Zeng G, Yang Q, Zhang J, Zhu X, Chen Q . Anti-tuberculosis treatment enhances the production of IL-22 through reducing the frequencies of regulatory B cell. Tuberculosis (Edinb). 2014; 94(3):238-44. DOI: 10.1016/j.tube.2013.12.003. View

2.
Qiu L, Huang D, Chen C, Wang R, Shen L, Shen Y . Severe tuberculosis induces unbalanced up-regulation of gene networks and overexpression of IL-22, MIP-1alpha, CCL27, IP-10, CCR4, CCR5, CXCR3, PD1, PDL2, IL-3, IFN-beta, TIM1, and TLR2 but low antigen-specific cellular responses. J Infect Dis. 2008; 198(10):1514-9. PMC: 2884371. DOI: 10.1086/592448. View

3.
Sivro A, Schuetz A, Sheward D, Joag V, Yegorov S, Liebenberg L . Integrin αβ expression on peripheral blood CD4 T cells predicts HIV acquisition and disease progression outcomes. Sci Transl Med. 2018; 10(425). PMC: 6820005. DOI: 10.1126/scitranslmed.aam6354. View

4.
Fine P . Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995; 346(8986):1339-45. DOI: 10.1016/s0140-6736(95)92348-9. View

5.
Alvarez Y, Tuen M, Shen G, Nawaz F, Arthos J, Wolff M . Preferential HIV infection of CCR6+ Th17 cells is associated with higher levels of virus receptor expression and lack of CCR5 ligands. J Virol. 2013; 87(19):10843-54. PMC: 3807416. DOI: 10.1128/JVI.01838-13. View